Action CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Creative Medical Technology Holdings, Inc.

Actions

CELZ

US22529Y4089

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 10/05/2024 		Varia. 5j. Varia. 1 janv.
4,35 USD +1,16% Graphique intraday de Creative Medical Technology Holdings, Inc. -1,02% -5,64%
10/05 Creative Medical Technology Holdings, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
22/03 Creative Medical Technology Holdings, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Creative Medical Technology Holdings Provides Corporate Update
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures
Creative Medical Shares Rally Premarket on FDA Orphan Designation
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony
Top Premarket Gainers
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem
Creative Medical Technology Holdings Provides Corporate Update
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CELZ
  4. Actualités Creative Medical Technology Holdings, Inc.
  5. Autres langues